In a recent study published in Value in Health, researchers investigated how real world evidence (RWE) impacted decision-making by the European Medicines Agency. RWE was especially useful in assessing adverse events and tracking patient outcomes. The authors remark, “Ensuring transparency of RWE […]
ISPOR Article on Prescription Drug Price Variation in Last Decade
In a recent article published in Value in Health, the authors investigate pharmaceutical drug prices. They note significant variation among payers; Veterans Affairs drug prices were some of the lowest compared to other payers. “We combine publicly-available data on branded drug prices from a host […]
ISPOR Seeks Survey Respondents to Identify Key HEOR Trends
The Professional Society for Health Economics and Outcomes Research (ISPOR) has issued a survey to understand key trends in health economics and outcomes research (HEOR). Survey results will inform scientific initiatives, improve interdisciplinary communication, and aid in the preparing for future […]
PhRMA President Discusses Patient Centricity in Value Assessments
President of Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Eileen Cannon shared her thoughts on adding a patient-centered component to value assessments. She notes distinctions between traditional measures of outcomes and outcomes reported by patients. Cannon remarks, […]
ISPOR Article Evaluates Bias Assessment Tools in HEOR
An article published in ISPOR’s Value in Health journal discusses bias assessment tools. The authors distinguish between absolute and relative value judgements, noting significant variability based on the selected tool. “Tool independence is an important attribute of a bias assessment tool. On […]
Register Today for ISPOR Short Course on Decision-Grade RWE
The International Society for Pharmacoeconomics and Outcomes (ISPOR) will hold a short course from 9:00 AM to 1:30 PM EDT on Tuesday, August 31st on developing high-level real world evidence (RWE). The course will include a hands-on portion where participants make use of a US insurance claims […]
Upcoming ISPOR Webinar on Successfully Incorporating External Controls Into Oncology RWE Studies
The International Society for Pharmacoeconomics and Outcomes (ISPOR) will host a webinar on August 12th at 2:00 PM EDT on successfully using external controls in oncology real world evidence (RWE) studies. A diverse group of speakers including statisticians, clinicians, and RWE experts will discuss […]
ISPOR Article Highlights Substantial Yet Forgotten Impact of Healthcare on Patient Caregivers
An article published in the May/June issue of ISPOR’s Value & Outcomes Spotlight highlights the burden of disease on patient carers, an often-forgotten aspect of patient care. The authors note that some diseases, including dementia and Alzheimer’s disease, are associated with substantial […]
ISPOR’s Value & Outcomes Spotlight Features Visual Representation Detailing How HEOR Impacts Healthcare Policy and Decision-Making
An article in ISPOR’s May/June issue of its Value & Outcomes Spotlight magazine visually details how health economics and outcomes research (HEOR) can impact policy and decision-making. The authors highlight 4 components that link HEOR and policy. “The ISPOR Student Network presents a […]
New ISPOR Article Highlights Need for Clearly Defining Fit-For-Purpose RWD in Oncology Research, Reveals UReQA RWD Selection Framework
Fit-for-purpose real world data (RWD) is an attractive source of decision-making data. Multiple stakeholders, including regulatory affairs professionals and payers, have increasingly turned to such data. However, a lack of consensus surrounding the term leads to confusion and uncertainty, according […]
